NCT06485739View on ClinicalTrials.gov

Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2028

Study Completion Date

September 1, 2028

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Irinotecan liposomes combined with cisplatin/carboplatin

Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT06485739 - Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter